TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04185662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucralose
Description: daily intake different dose of artificial sweeteners sucralose or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucralose
Description: daily intake different dose of artificial sweeteners sucralose or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucralose
Description: daily intake different dose of artificial sweeteners sucralose or placebo
Study: NCT00790218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF102
Description: CF102 capsules twice daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF102
Description: CF102 capsules twice daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF102
Description: CF102 capsules twice daily by mouth
Study: NCT02412527

Intervention type: OTHER
Intervention: Patch III heart rate sensor

Intervention type: OTHER
Intervention: Patch III heart rate sensor

Intervention type: OTHER
Intervention: Patch III heart rate sensor

Intervention type: OTHER
Intervention: Patch III heart rate sensor
Study: NCT02124928

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
Study: NCT03138291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnodent
Description: Each pregnant women will be treat with a Somnodent
Study: NCT01378091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily.
Study: NCT02703649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
Study: NCT05525065

Intervention type: DRUG
Intervention: GlucoCorticoid
Description: Glucocorticoid as calculated in prednisone oral equivalents.

Intervention type: DRUG
Intervention: GlucoCorticoid
Description: Glucocorticoid as calculated in prednisone oral equivalents.
Study: NCT02596425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 40 cmH2O
Description: The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 cmH2O
Description: The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive deflation
Description: In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
Study: NCT01922804

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT04234932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil Ophthalmic
Description: Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
Study: NCT04634318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory rehabilitation program (RR).
Description: Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory tele-rehabilitation program (TRR).
Description: Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
Study: NCT01829867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0031
Study: NCT00728728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: Pregnenolone
Description: Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00732706

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sartorius Muscle Twitch
Description: Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Quadriceps Muscle Twitch
Description: Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
Study: NCT02768389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Subjects receive Bevacizumab as standard of care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).
Study: NCT03930667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clips

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: knotting
Study: NCT04808310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio
Description: Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of angiographic severity of the stenosis
Description: The indication to coronary stent intervention will be based on angiography
Study: NCT00798876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
Study: NCT00090766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: po daily (dose based on body surface area and CrCL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: po daily (dose based on body surface area and CrCL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valganciclovir [Valcyte]
Description: po daily (dose based on body surface area and CrCL)
Study: NCT00606294

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine-18-labeled fluoro-misonidazole (18F-FMISO)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine-18-labeled fluoro-misonidazole (18F-FMISO)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/CT scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/CT scan
Study: NCT00486512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Study: NCT00988377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein 10-40 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein 10-40 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein 10-40 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein 10-40 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water control
Description: Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
Study: NCT02697058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX2398 + 5-FU/calcium levofolinate
Description: BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX2398 + 5-FU/calcium levofolinate
Description: BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU/calcium levofolinate
Description: 5-FU/calcium levofolinate alone
Study: NCT04336007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistive Diathermy (INDIBA® Activ Ct9)
Description: Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Resistive Diathermy OFF (INDIBA® Activ Ct9)
Description: Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: This group will warm-up as they usually do in competitions, for later time trial measuring.
Study: NCT00837239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuaChanSu
Description: 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 ml saline only administered as a 2 hour infusion by central line.
Study: NCT01154322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pixi pediatric mask
Description: The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
Study: NCT04363944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mRehab
Description: mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mRehab
Description: mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
Study: NCT03256136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: will allow the body's immune system to work against tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: will allow the body's immune system to work against tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: will allow the body's immune system to work against tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: will allow the body's immune system to work against tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Chemo therapy
Study: NCT00798876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E supplement
Description: Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Western Diet
Description: Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet
Description: Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Examination
Description: Subjects will have a routine medical exam.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medical Examination
Description: Subjects will have a routine medical exam.
Study: NCT04663698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
Study: NCT00798876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Interview
Description: Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
Study: NCT04663698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
Study: NCT03379168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline injection will act as a placebo group.
Study: NCT04663698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 5
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 5
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 5
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
Study: NCT03256136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Chemo therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: will allow the body's immune system to work against tumor cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: will allow the body's immune system to work against tumor cells
Study: NCT04110444

Intervention type: DRUG
Intervention: Sildenafil
Description: oral sildenafil t.d.s for high-risk pregnancies
Study: NCT01171742

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intermittent hepatic inflow occlusion (IHIO)
Description: Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent hepatic inflow occlusion (IHIO)
Description: Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
Study: NCT00798876

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Interview
Description: Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: 40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw
Description: 40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Subjects will undergo a radical prostatectomy as part of their standard of care.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radical Prostatectomy
Description: Subjects will undergo a radical prostatectomy as part of their standard of care.
Study: NCT04663698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 5
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 10
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MESH-Resistor 10
Description: Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 7
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 7
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated Resistor 7
Description: Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
Study: NCT00866190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.